Saturday, April 10, 2021
Tags Sinopharm

Tag: Sinopharm

Economy

Sinopharm Says Test Subjects for World’s First COVID-19 Inactivated Vaccine All Produced High Concentrations of Antibodies

CBNEditor - 0
Chinese state-owned pharmaceutical giant Sinopharm has hailed the success of trials of its COVID-19 inactivated vaccine, pointing to the production of high-concentrations...
Read more
Economy

Sinopharm Chairman Says COVID-19 Vaccine Has Proven Successful after Serving as Test Subject Himself

CBNEditor - 0
Sinopharm Group has hailed the safety and efficacy of a new COVID-19 vaccine after senior executives from the company served as trial...
Read more
Economy

Sinopharm Working on Coronavirus Vaccine, Officials Say Product Could Hit Market in Several Months

CBNEditor - 0
Chinese pharmaceutical giant Sinopharm Group Co., Ltd. says it's working on the development of a vaccine for the novel coronavirus, with domestic...
Read more

Most Read

Digital Renminbi Makes Its Debut on Renmin University Campus

Fintech CBNEditor - 0
Ongoing trials of China's Digital Renminbi have brought the central bank digital currency to one of the country's most prestigious tertiary institutions....
Read more

China’s Services Exports Surge over 20% since Start of 2021, Imports Plunge by More Than 18%

Economy CBNEditor - 0
China has seen a sharp rise in its exports of services since the start of 2021, in tandem with a plunge in...
Read more

Liquidity to Come Under Modest Pressure in April Following Funds Contraction of 30 Billion Yuan in March

Banking CBNEditor - 0
Liquidity in the Chinese finance system is expected to come under modest pressure in the month of April as a result of...
Read more

China Co-chairs G20 Sustainable Finance Study Group with United States

Economy CBNEditor - 0
China will play a leading role in efforts by the G20 to develop solutions for the challenges faced by the global sustainable...
Read more

ABOUT US

China Banking News covers all the latest news and development in the Chinese finance and fintech sectors.

Contact us: [email protected]

FOLLOW US